NCT01060904 - A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions

Disease, Hodgkin

Interventions

DRUG

brentuximab vedotin

0.6-1.2 mg/kg IV every 2 weeks

DRUG

doxorubicin

25 mg/m2 IV every 2 weeks

DRUG

vinblastine

6 mg/m2 IV every 2 weeks

DRUG

dacarbazine

375 mg/m2 IV every 2 weeks

DRUG

bleomycin

10 units/m2 IV every 2 weeks

DRUG

brentuximab vedotin

0.9-1.2 mg/kg IV every 2 weeks

Trial Locations (4)

UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill

Mayo Clinic, Rochester

MD Anderson Cancer Center / University of Texas, Houston

British Columbia Cancer Agency - Vancouver Centre, Vancouver